As part of the assessment of substances that may have endocrine disrupting properties, the European Commission has asked the SCCS to evaluate the safety of the UV filter Ethylhexyl Methoxycinnamate (EHMC). The Scientific Committee has just published its final Opinion.
Background
Ethylhexyl Methoxycinnamate (EHMC) (CAS No.5466-77-3/83834-59-7, EC No.226-7757/629-661-9) is regulated as a UV-filter in sunscreen products in a concentration up to 10% (Annex VI/12).
During the call for data in 2021 on endocrine disruptors to be assessed as a priority, stakeholders submitted scientific evidence to demonstrate the safety of Ethylhexyl Methoxycinnamate as UV-filter in cosmetic products. The Commission then requested the SCCS to carry out a safety assessment on Ethylhexyl Methoxycinnamate in view of the information provided.
The Scientific Committee adopted its preliminary Opinion in October 2024, saying it could not conclude on the safety of EHMC, due to insufficient information to rule out genotoxicity.
For an exhaustive background information, see the articles
• Endocrine disruptors: 2nd call for data from the European Commission, CosmeticOBS, 22 February 2021
• Ethylhexyl Methoxycinnamate: request for an Opinion to the SCCS, CosmeticOBS, 11 March 2024 • Ethylhexyl Methoxycinnamate: preliminary Opinion of the SCCS, CosmeticOBS, 18 November 2024
This Opinion has been subject to a commenting period of minimum eight weeks after its initial publication (from 12 November 2024 to 17 January 2025). Comments received during this period were considered by the SCCS.
For this Opinion, main changes …
